{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:12:56Z","timestamp":1775473976491,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00198-024-07082-9","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T11:01:59Z","timestamp":1713006119000},"page":"1299-1302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9809-1014","authenticated-orcid":false,"given":"K.","family":"McCarroll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Neville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"key":"7082_CR1","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1007\/s00198-016-3534-6","volume":"27","author":"R Lindsay","year":"2016","unstructured":"Lindsay R, Krege JH, Marin F et al (2016) Teriparatide for osteoporosis: importance of the full course. Osteoporos Int 27:2395\u20132410. https:\/\/doi.org\/10.1007\/s00198-016-3534-6","journal-title":"Osteoporos Int"},{"issue":"1","key":"7082_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.55729\/2000-9666.1010","volume":"12","author":"J Milosavljevic","year":"2022","unstructured":"Milosavljevic J, Thomas AM (2022) Teriparatide associated late hypercalcemia: a report of two cases and literature review. J Community Hosp Intern Med Perspect 12(1):54\u201358","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"7082_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"7082_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s00259-011-1974-y","volume":"39","author":"AE Moore","year":"2012","unstructured":"Moore AE, Blake GM, Taylor KA, Ruff VA, Rana AE, Wan X, Fogelman I (2012) Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis. Eur J Nucl Med Mol Imaging 39(2):326\u2013336","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7082_CR5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00198-018-4445-5","volume":"29","author":"MA Paggiosi","year":"2018","unstructured":"Paggiosi MA, Yang L, Blackwell D, Walsh JS, McCloskey E, Peel N, Eastell R (2018) Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study. Osteoporos Int 29(6):1367\u20131378","journal-title":"Osteoporos Int"},{"issue":"2","key":"7082_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4103\/0253-7613.93869","volume":"44","author":"C Karatoprak","year":"2012","unstructured":"Karatoprak C, Kayatas K, Kilicaslan H, Yolbas S, Yazimci NA, G\u00fcm\u00fcskemer T, Demirtun\u00e7 R (2012) Severe hypercalcemia due to teriparatide. Indian J Pharmacol 44(2):270\u2013271","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"7082_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ckj\/sfs148","volume":"6","author":"N Ayasreh","year":"2013","unstructured":"Ayasreh N, Fernandez-Llama P (2013) MJ Lloret, Iara Da Silva, Jose Ballar\u00edn, Jordi Bover, Recombinant PTH associated with hypercalcaemia and renal failure. Clin Kidney J 6(1):93\u201395. https:\/\/doi.org\/10.1093\/ckj\/sfs148","journal-title":"Clin Kidney J"},{"issue":"1","key":"7082_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.11005\/kjbm.2012.19.1.53","volume":"19","author":"JW Koo","year":"2012","unstructured":"Koo JW, Lee JH, Jang NE, Kim H, Seok HY, So YR, Shin AR, Cho JH, Lee SH (2012) A case of severe hypercalcemia after treatment with teriparatide for osteoporosis. Korean J Bone Metabol 19(1):53\u201358","journal-title":"Korean J Bone Metabol"},{"key":"7082_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/802473","volume":"2014","author":"N Thiruchelvam","year":"2014","unstructured":"Thiruchelvam N, Randhawa J, Sadiek H, Kistangari G (2014) Teriparatide induced delayed persistent hypercalcemia. Case Rep Endocrinol 2014:802473. https:\/\/doi.org\/10.1155\/2014\/802473","journal-title":"Case Rep Endocrinol"},{"issue":"5","key":"7082_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00774-014-0564-z","volume":"32","author":"M Hajime","year":"2014","unstructured":"Hajime M, Okada Y, Mori H, Tanaka Y (2014) A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. J Bone Miner Metab 32(5):601\u2013604","journal-title":"J Bone Miner Metab"},{"key":"7082_CR11","doi-asserted-by":"publisher","first-page":"SAT-505","DOI":"10.1210\/js.2019-SAT-505","volume":"3","author":"D Sistla","year":"2019","unstructured":"Sistla D, Mehrotra N, Mon SY (2019) SAT-505 A A rare case of teriparatide induced persistent hypercalcemia. J Endoc Soc 3:SAT-505","journal-title":"J Endoc Soc"},{"issue":"1","key":"7082_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11914-008-0003-y","volume":"6","author":"PD Miller","year":"2008","unstructured":"Miller PD (2008) Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep 6(1):12\u201316","journal-title":"Curr Osteoporos Rep"},{"key":"7082_CR13","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJM200505053521822","volume":"352","author":"AA Licata","year":"2005","unstructured":"Licata AA (2005) Osteoporosis, teriparatide, dosing of calcium and vitamin D. N Engl J Med 352:1930\u20131931","journal-title":"N Engl J Med"},{"issue":"19","key":"7082_CR14","doi-asserted-by":"publisher","first-page":"1434e1441","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344(19):1434e1441","journal-title":"N Engl J Med."},{"key":"7082_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"E Orwoll","year":"2003","unstructured":"Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman J-M, Clancy A, Gaich G (2003) The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9\u201317","journal-title":"J Bone Miner Res"},{"issue":"10117","key":"7082_CR16","doi-asserted-by":"publisher","first-page":"230e240","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 391(10117):230e240","journal-title":"Lancet."},{"issue":"13","key":"7082_CR17","doi-asserted-by":"publisher","first-page":"1207e1215","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 349(13):1207e1215","journal-title":"N Engl J Med."},{"key":"7082_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","volume":"87","author":"J Satterwhite","year":"2010","unstructured":"Satterwhite J, Heathman M, Miller PD et al (2010) Pharmacokinetics of teriparatide (rhPTH[1\u201334]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int 87:485\u2013492","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"7082_CR19","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.bone.2012.02.635","volume":"50","author":"F Cosman","year":"2012","unstructured":"Cosman F, Dawson-Hughes B, Wan X, Krege JH (2012) Changes in vitamin D metabolites during teriparatide treatment. Bone 50(6):1368\u20131371","journal-title":"Bone"},{"issue":"1","key":"7082_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbm4.10005","volume":"1","author":"KM Kim","year":"2017","unstructured":"Kim KM, Lee SY, Rhee Y (2017) Influence of dosing interval and administration on the bone metabolism, skeletal effects, and clinical efficacy of parathyroid hormone in treating osteoporosis: a narrative review. JBMR Plus 1(1):36\u201345","journal-title":"JBMR Plus"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07082-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T06:06:29Z","timestamp":1719468389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07082-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["7082"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07082-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}